Polyplus-transfection Enters Reagent Deal with Roche Glycart | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Polyplus-transfection announced today it has granted a non-exclusive license to Roche Glycart for use of polyethylenimine for in vitro transfection applications for research purposes.

As a result, Roche Glycart will be able to use the transfection reagent to produce antibody-based products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.